EGFRi/METi 队列中的另一名患者发生CTNNB1 p.S45P突变。在最后一次随访时,即开始接受奥希替尼联合特泊替尼治疗后14.0个月,该患者仍然活着且无进展。 一名患者出现可检测到的PIK3CA p.E542A突变,并且在使用奥希替尼加特泊替尼不到1个月后出现病情进展。 在EGFRi/METi队列中未观察到MET、ERBB2(HER2)、KRAS和...
具体而言,排除了已知携带EGFR,KRAS,BRAF或ERBB2突变或ALK或ROS1重排的患者。 其中,MET外显子14跳跃是最常见的突变,发生在10名患者(19%)中。腺癌和鳞状组织学均可见MET外显子14跳跃。一名患者共存PI3KCA E545K和CTNNB1突变。 RET和NRG1的重排也是该队列患者的常见事件。值得一提的是,两名被认为ALK阴性的患者PC...
ERBB2突变的患者中NKX2-1扩增(19.4%),ERBB2扩增(14.4%)和RB1突变(8.9%)比较常见,而TP53 (51.7%), CDKN2A(27.2%), CDKN2B (17.2%), PIK3CA (5%) and CTNNB1(4.4%) 和MDM2 扩增 (7.2%)在ERBB2突变的患者中的占比与总体的非小细胞肺癌中的占比类似。
35,36] and stained using the clone SP44 (Ventana, Oro Valley, USA), as described in Supplementary TableS1. MET was scored from 0 to 3. Score 3 was assigned if ≥ 50% of tumor cells were stained with strong intensity; score 2 by ≥ 50% of tumor cells with moderate or h...
The resultant mouse tumors showed similar transcriptomes to human HCC samples with concomitant CTNNB1 mutations and MET overexpression. These data argue that while dominantly activating mutants of β-catenin are oncogenic, inhibiting the oncogenic signaling pathway generates a prooncogenic microenvironment, ...
Genetic characterization by multiplex ligation-dependent probe amplification and analysis of phosphotyrosine signaling by MALDI-TOF mass spectrometry analysis revealed the activation of MET and SRC signaling, associated with the amplification of MET and of CTNNB1 and CCND1 genes, respectively. The ...
Association of CTNNB1 (β-Catenin) Alterations, Body Mass Index, and Physical Activity With Survival in Patients With Colorectal Cancer level of long interspersed nucleotide element 1 methylation, mutations in KRAS, BRAF, or PIK3CA, and tumor protein p53.Colorectal cancer-specific mortality ... T...
的已知热点,包含AKT1、ALK、AR、BRAF、CDK6、CTNNB1、EGFR、ERBB2、ERBB3、ESR1、FGFR1、 FGFR2、FGFR3、HRAS、IDH1、IDH2、KIT KRAS、MAP2K1、NRAS、NTRK1、NTRK2、NTRK3、PDGFRA、 PIK3CA、RET、ROS1和TP53,用于检测异常变体和拷贝数变异。Caris MI转录组测试涵盖整个 转录组,用于检测基因表达和转录物上的...
d. p.G274 _P277del (del)[4] Others KRAS: p.G12D (sub)[1; 2] CTNNB1: p.G34E (sub)[1] PIK3CA: p.E453K (sub)[1] MET: amp[5] PIK3CA: p.E545K (sub)[1] KRAS: amp[2] FBXW7: R465C[1] - MET: amp[5] Information about genomic alterations of the gastric c...
EGFRi/METi 队列中的另一名患者发生CTNNB1 p.S45P突变。在最后一次随访时,即开始接受奥希替尼联合特泊替尼治疗后14.0个月,该患者仍然活着且无进展。 一名患者出现可检测到的PIK3CA p.E542A突变,并且在使用奥希替尼加特泊替尼不到1个月后出现病情进展。